Zillow Group (NASDAQ:Z) had its price target hoisted by stock analysts at Benchmark from $100.00 to $120.00 in a note issued to investors on Thursday, The Fly reports. The firm currently has a "buy" rating on the financial services provider's stock. Benchmark's target price would indicate a potential upside of 24.58% from the company's current price.
A number of other brokerages have also recently issued reports on Z. Zelman & Associates upgraded Zillow Group from a "hold" rating to a "buy" rating in a report on Monday. Standpoint Research lowered Zillow Group from a "buy" rating to a "hold" rating in a research report on Monday, August 3rd. Morgan Stanley raised their target price on Zillow Group from $46.00 to $64.00 and gave the company an "equal weight" rating in a research report on Tuesday, August 4th. BidaskClub raised Zillow Group from a "buy" rating to a "strong-buy" rating in a report on Wednesday, September 16th. Finally, Needham & Company LLC lifted their target price on Zillow Group from $110.00 to $125.00 and gave the company a "buy" rating in a report on Wednesday. Four analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of "Buy" and an average target price of $103.00.
Zillow Group stock opened at $96.32 on Thursday. The business has a 50 day moving average of $83.97 and a 200-day moving average of $58.93. Zillow Group has a 1 year low of $20.04 and a 1 year high of $102.05. The company has a debt-to-equity ratio of 0.50, a current ratio of 10.08 and a quick ratio of 9.73. The company has a market capitalization of $21.86 billion, a P/E ratio of -49.14 and a beta of 1.21.
Zillow Group (NASDAQ:Z) last released its earnings results on Thursday, August 6th. The financial services provider reported ($0.41) earnings per share for the quarter. The firm had revenue of $768.35 million for the quarter. Zillow Group had a negative net margin of 11.54% and a negative return on equity of 9.76%.
In other news, insider Stanley B. Humphries sold 37,578 shares of the company's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $87.73, for a total transaction of $3,296,717.94. Following the transaction, the insider now directly owns 72,783 shares of the company's stock, valued at $6,385,252.59. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Richard N. Barton sold 35,000 shares of the company's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $58.12, for a total value of $2,034,200.00. Following the transaction, the chief executive officer now directly owns 175,536 shares in the company, valued at $10,202,152.32. The disclosure for this sale can be found here. Insiders sold 2,585,622 shares of company stock worth $197,675,370 over the last three months. Corporate insiders own 19.87% of the company's stock.
A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Zillow Group by 11.3% in the second quarter. Vanguard Group Inc. now owns 11,122,489 shares of the financial services provider's stock valued at $640,767,000 after acquiring an additional 1,133,096 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its position in Zillow Group by 7.8% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,942,545 shares of the financial services provider's stock worth $342,350,000 after buying an additional 427,864 shares in the last quarter. Eminence Capital LP increased its position in Zillow Group by 36.1% in the first quarter. Eminence Capital LP now owns 4,394,300 shares of the financial services provider's stock worth $158,283,000 after buying an additional 1,166,538 shares in the last quarter. Sands Capital Management LLC purchased a new stake in Zillow Group in the first quarter worth about $142,696,000. Finally, Zevenbergen Capital Investments LLC increased its position in Zillow Group by 1.1% in the first quarter. Zevenbergen Capital Investments LLC now owns 1,970,370 shares of the financial services provider's stock worth $70,972,000 after buying an additional 21,775 shares in the last quarter. 76.11% of the stock is currently owned by institutional investors.
About Zillow Group
Zillow Group, Inc operates real estate and home-related brands on mobile and the Web in the United States. The company offers a portfolio of brands and products to empowering consumers with unparalleled data, inspiration, and knowledge around homes and connecting them with real estate professionals. Its brands focus on various stages of the home lifecycle, including renting, buying, selling, and financing.
See Also: Retained Earnings
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Great Biotech Stocks That Don’t Depend on a Coronavirus Cure
Biotech stocks are some of the most volatile for investors to include in their portfolio. And that volatility can be hard to predict. Biotech companies don’t have a firm correlation with the overall economy. And what can add to the challenge is that many of these companies are small-cap companies that are not well-known names.
These small biotech stocks may shoot higher based on a vaccine or drug candidate that gets national attention. But these small-cap stock also reflect the adage of letting the buyer beware. Because the stark reality for many investors is that the vast majority of these treatments never make it past clinical trials. And that means that a stock that goes up rapidly can move down just as fast.
We’re seeing that right now with the multitude of companies that are competing in the race towards a vaccine and/or treatment for Covid-19 and the novel coronavirus that causes the disease. And if you’ve been good at timing the market, you could have made some good money on some of these candidates.
Of course, if you held the stock too long, you could have lost your shirt as well.
That doesn’t mean however that buy and hold investors should avoid the biotech sector altogether. There are still some attractively priced small-cap biotech companies that are working on treatments for a range of conditions that provide them with a large addressable base. And we’ve identified seven of these stocks in this special presentation.
View the "7 Great Biotech Stocks That Don’t Depend on a Coronavirus Cure".